Efficacy of Pentoxifylline in diabetic nephropathy

Evaluation of the effects of combination therapy of pentoxifylline and losartan in comparison with losartan alone on diabetic nephropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190806044451N2

Enrollment

Registered

2021-01-09

Start date

2019-07-13

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Type 2 Diabetes. Condition 2: Diabetic Nephropathy. Type 2 diabetes mellitus ????????? ????????

Interventions

Intervention 1: Intervention group: Add oral Pentoxifylline 400 mg (twice daily) to oral Losartan 50 mg (twice daily) for 3 months. Intervention 2: Control group: Continue treatment with oral Losartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients treated with insulin and oral agents GFR above 30 cc / min / 1.73 m2 albuminuria above 300 mg/g

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Type 1 diabetes Pentoxifylline allergy Chronic heart failure Uncontrolled hypertension Other medicines that affect albuminuria Cerebral hemorrhage Extensive retinal hemorrhage ESRD, GFR <30 Pregnancy Hyperkalemia (high potassium) 5.5 before or during the study)

Design outcomes

Primary

Measure	Time frame
Random Urin Albumin/Creatinine. Timepoint: 3 months before intervention and before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.	—

Secondary

Measure	Time frame
Creatinin. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.;Hemoglobin A1c. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.;Blood pressure. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Sphygmomanometer.;Body mass index. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: meter & Balance.;Fasting blood sugar (FBS). Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.;Pentoxifylline Complications. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: History taking.	—

Measure

Time frame

Creatinin. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.;Hemoglobin A1c. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.;Blood pressure. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Sphygmomanometer.;Body mass index. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: meter & Balance.;Fasting blood sugar (FBS). Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: Lab test.;Pentoxifylline Complications. Timepoint: Before starting pentoxifylline and 3 months after starting pentoxifylline. Method of measurement: History taking.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Jalali

Zanjan University of Medical Sciences

somayehjalali10@yahoo.com+98 24 3377 0758

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026